Abstract
Gastrointestinal stromal tumors (GISTs) are the most common type of gastrointestinal mesenchymal tumors, although metastasis to the perigastric lymph nodes is relatively rare, compared with liver or peritoneal metastasis. In this report, we describe a case of stomach GIST with a solitary simultaneous metastasis in the left axillary lymph node. A 68-year-old man was diagnosed with a large upper-stomach GIST, and computed tomography and positron emission tomography revealed masses in the left axilla and right mediastinum. We did not detect evidence of metastases to the liver, or other sites including the perigastric lymph nodes, although findings from the surgically resected axillary lymph nodes were compatible with GIST metastasis. Treatment using imatinib markedly reduced the gastric and mediastinal lesions, and this response persisted for 3 years. The patient subsequently experienced rapid growth of the gastric lesion without mediastinal or axilla recurrence, which required palliative surgery. Despite continuing medical treatment (sunitinib and regorafenib), the patient died of liver metastases 23 mo after the surgery. Based on our findings, it appears that the axillary lymph nodes can be a potential metastatic site for GIST metastasis.
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are the most common type of gastrointestinal mesenchymal tumor, although GIST only accounts for approximately 1% of gastric malignancies [1] . GISTs frequently metastasize to the liver or peritoneum, although lymph node metastasis is very rare [2] , even to the perigastric area. Therefore, we report the first documented case of stomach GIST with simultaneous axillary lymph node metastasis.
Case RePORT
A 68-year-old man was admitted to our hospital after complaining of anorexia and obvious weight loss. Gastroscopy revealed a large tumor with ulceration in the upper stomach body (Figure 1) , and histological evaluation confirmed a diagnosis of a GIST (positive for c-kit and CD34). The mitotic index was 5/50 in high-power field and the MIB-1 labeling index was 10%. Computed tomography (CT) and positron emission tomography revealed a primary gastric tumor (diameter: 5 cm), a right mediastinal tumor (diameter: 2 cm), and a left axilla mass (diameter: 1 cm) ( Figure  2 ). Based on these findings, we performed a complete gross excision of the left axilla mass. The specimen was 1.4 cm in diameter, and there was no extranodal extension, it exhibited monotonous spindle cells ( Figure  3A-D) and was diagnosed as a metastasis of the GIST, because it exhibited positive immunohistochemical staining for c-kit ( Figure 3E ) and DOG1 ( Figure 3F ), the mitotic index was 15/50 in high-power field and the MIB-1 labeling index was 10%. Based on these findings, we started treatment using oral imatinib (400 mg/d), and in the next year, after starting imatinib, we followed up the patient every 3 mo by using CT and every 6 mo by using PET. The 6-mo follow-up revealed rapid response of the primary lesion and complete remission in the mediastinal lymph nodes. However, after 3 years of imatinib treatment, the primary gastric tumor exhibited rapid growth that resulted in obstructive symptoms and continuous bleeding, although we did not detect recurrence in the mediastinal and axillary lymph nodes. We performed total gastrectomy as palliative surgery, and all 13 resected perigastric lymph nodes were negative for metastasis; the mitotic index was 20/50 in high-power field and the MIB-1 labeling index was 30%. The patient subsequently recovered, and we started postoperative adjuvant treatment using imatinib. However, liver metastases appeared after 13 mo of treatment using imatinib, which we attempted to treat using regorafenib because gene sequence analysis of the tumor showed a KIT exon 11 mutation. The liver metastasis increased 2 mo later, and we started treatment with sunitinib. However, the patient developed renal dysfunction, and died of the liver metastasis 23 mo after the surgery with gastretomy.
DIsCUssION
GIST is the most common type of gastrointestinal mesenchymal tumor, and commonly exhibits mutations in the c-kit proto-oncogene [3] . GIST frequently metastasizes to the liver or peritoneum, although nodal metastasis is very rare [2] . Among 200 reported patients with digestive tract GIST, 94 patients exhibited metastasis, which included 61 liver metastases (65%), 20 peritoneal metastases (21%), and only 6 lymph node metastases (6%) [4] . To the best of our knowledge, there is only one documented case of distant lymph node metastasis from a stomach GIST, and that case involved inguinal lymph node metastasis [5] . Although a few cases of peripheral lymph nodes metastasis from GIST have been reported [6] , the present case is the first documented case of a GIST presenting with solitary axillary lymph node metastasis. 
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The three major routes of metastasis to the axillary lymph nodes are clearly documented in lung cancer [7, 8] . The first route involves newly developed lymphatic channels that arise from the pleural lesions of adhesive lung tumors. The second route involves retrograde spread in the presence of supraclavicular 
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lymph node metastasis. The third route involves systemic axial lymph node metastasis. In this context, systemic metastases could be caused by the primary tumor invading nearby blood vessels and the subsequent dissemination of tumor cells into the venous system through the thoracic duct [9, 10] . In the present case, the tumor was likely caused by systemic metastasis, as the recurrence was only detected in the right mediastinum, without lung or supraclavicular lymph node metastases.
Tumor size, location, mitotic rate, and C-KIT and PDGFRA genotype are the major determinants of the malignant potential of the tumor, and have significant impact on prognosis [11] . In the TNM (tumor-nodemetastasis) system for GISTs, the presences of lymph node metastasis is classified as stage Ⅳ, which generally portends a poor prognosis, but cases with longterm survival have also been reported [5, 12] . Valadao reported that lymph node metastasis is not related to poor prognosis; however, the study included a small number of patients [13] . Furthermore, it is unclear whether there is a difference of prognosis according to the site of lymph node metastasis, because reports of distant lymph node metastasis are very rare. The appropriate therapy for GIST with distant metastasis remains controversial. Surgery is recommended if curative resection is possible, although imatinib therapy is occasionally selected in cases that have complications or may require expansive surgery. In the present case, we performed complete gross excision of the left axilla mass, and imaging revealed that only right mediastinum metastasis remained. However, we selected imatinib therapy, based on the tumor's stage and the patient's surgical stress. Six months of imatinib therapy markedly reduced the gastric lesion and the mediastinal lesion completely disappeared. In this context, resection of residual disease after imatinib pre-treatment is feasible in patients with metastatic GIST, even those with advanced hepatic and peritoneal metastasis [14] , and surgery after achieving the best clinical response may be associated with a survival benefit (vs historical patients who were treated using imatinib alone) [15] . Therefore, we assumed that the distant metastasis had been controlled by imatinib and that curative resection was possible. However, the patient refused to undergo gastrectomy and elected to continue receiving imatinib. Unfortunately, the primary lesion exhibited rapid regrowth after 3 years of imatinib treatment without reappearance of the mediastinal lesion or other distinct metastases, which led to obstructive symptoms and continuous bleeding. At this point, we performed palliative total gastrectomy and provided ongoing medical treatment (sunitinib and regorafenib), although the patient ultimately died of liver metastases at 23 mo after the surgery. Nevertheless, the patient did not exhibit signs of distant lymph node metastasis.
In conclusion, the axillary lymph nodes can be a site of GIST metastasis, and imatinib chemotherapy may be useful for controlling distant lymph node metastasis from GIST. Although we performed a resection for the original lesion because the distant metastasis had been controlled by imatinib, the appropriate therapy for GIST with distant metastasis remains controversial. Further studies are needed to clarify the duration of chemotherapy and an appropriate surgical intervention that will be effective for treating distant lymph node metastasis.
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COMMeNTs

Case characteristics
A 68-year-old man was admitted to our hospital after complaining of anorexia obvious weight loss.
Clinical diagnosis
The patient was diagnosed with malignancies in the stomach.
Differential diagnosis
Gastric cancer.
Imaging diagnosis
Gastroscopy revealed a large tumor with ulceration in the upper stomach body. Computed tomography and positron emission tomography revealed a primary gastric tumor and a left axilla mass.
Pathological diagnosis
Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis.
Treatment
Surgical resection and chemotherapy (imatinib, regorafenib and sunitinib).
Related reports
There is only one documented case of distant lymph node metastasis from a stomach gastrointestinal stromal tumor (GIST), and that case involved inguinal lymph node metastasis.
Term explanation
The axillary lymph nodes can be a site of GIST metastasis.
Experiences and lessons
Imatinib chemotherapy may be useful for controlling distant lymph node metastasis from GIST.
Peer-review
This is the interesting case report. The authors described lymph node metastasis of GIST is very rare; therefore, the appropriate therapy for GIST with lymph node metastasis remains controversial. 
